Business
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
- Third quarter 2025 total revenue of $133 million - 2025 revenue guidance updated to $500 to $510 million - Phase 2b VISTAS topline data expected second
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Third quarter 2025 total revenue of $133 million\n\n- 2025 revenue guidance updated to $500 to $510 million\n\n- Phase 2b VISTAS topline data expected second quarter of 2026\n\n- Conference call to provide business updates today, November 4 at 1:30 p.m. PT / 4:30 p.m. ET\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2025 and provided a business update.\n\n“Mirum is well positioned heading into 2026 with strong commercial momentum and multiple upcoming catalysts,” said Chris Peetz, Chief Executive Officer of Mirum. \"Our third quarter results once again underscore the strength of our commercial medicines with continued strong performance. We also made important progress across the pipeline, including completing enrollment in the VISTAS PSC study, maintaining momentum in VANTAGE and EXPAND, and initiating our Phase 2 study in Fragile X Syndrome.”\n\nCommercial: Full year revenue guidance $500 to $510 million\n\n\nThird quarter 2025 global net product sales of $133.0 million.\n\n\nThird quarter 2025 LIVMARLI net product sales were $92.2 million, representing 56% growth over third quarter 2024 net product sales.\n\n\nBile Acid Medicines third quarter 2025 net product sales were $40.8 million, representing 31% growth over third quarter 2024 net product sales.\n\n\nPipeline: Building Momentum Toward Key 2026 and 2027 Readouts\n\n\nVolixibat VISTAS study in primary sclerosing cholangitis (PSC) enrollment complete; topline data expected in the second quarter of 2026.\n\n\nVolixibat VANTAGE study in primary biliary cholangitis (PBC) expected to complete enrollment in 2026; topline data expected in the first half of 2027.\n\n\nLIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions expected to complete enrollment in 2026; topline data expected in the first half of 2027.\n\n\nPhase 2 study for MRM-3379 in Fragile X Syndrome (FXS) initiated.\n\n\nCorporate and Financial: Executing with Financial Discipline and Operational Efficiency\n\n\nTotal revenue for the quarter ended September 30, 2025, was $133.0 million compared to $90.4 million for the quarter ended September 30, 2024.\n\n\nTotal operating expenses were $130.4 million for the quarter ended September 30, 2025, compared to $103.1 million for the quarter ended Septembe...